| Literature DB >> 33379241 |
Kasper Thystrup Karstensen1, Aleks Schein1, Andreas Petri1, Martin Bøgsted2,3, Karen Dybkær2,3, Shizuka Uchida1, Sakari Kauppinen1.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. Although significant progress has been made in recent years to treat DLBCL patients, 30%-40% of the patients eventually relapse or are refractory to first line treatment, calling for better therapeutic strategies for DLBCL. Long non-coding RNAs (lncRNAs) have emerged as a highly diverse group of non-protein coding transcripts with intriguing molecular functions in human disease, including cancer. Here, we review the current understanding of lncRNAs in the pathogenesis and progression of DLBCL to provide an overview of the field. As the current knowledge of lncRNAs in DLBCL is still in its infancy, we provide molecular signatures of lncRNAs in DLBCL cell lines to assist further lncRNA research in DLBCL.Entities:
Keywords: DLBCL; lncRNA; miRNA; rituximab
Year: 2020 PMID: 33379241 PMCID: PMC7838888 DOI: 10.3390/ncrna7010001
Source DB: PubMed Journal: Noncoding RNA ISSN: 2311-553X